{"id":744934,"date":"2014-09-04T14:15:00","date_gmt":"2014-09-04T14:15:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-accelerated-approval-of-keytruda-pembrolizumab-the-first-fda-approved-anti-pd-1-therapy\/"},"modified":"2023-03-22T00:04:51","modified_gmt":"2023-03-22T04:04:51","slug":"merck-receives-accelerated-approval-of-keytruda-pembrolizumab-the-first-fda-approved-anti-pd-1-therapy","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-accelerated-approval-of-keytruda-pembrolizumab-the-first-fda-approved-anti-pd-1-therapy\/","title":{"rendered":"Merck Receives Accelerated Approval of KEYTRUDA\u00ae (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy"},"content":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that the U.S. Food and Drug Administration (FDA) has<br \/>\n      approved KEYTRUDA\u00ae (pembrolizumab) at a dose of 2 mg\/kg every three<br \/>\n      weeks for the treatment of patients with unresectable or metastatic<br \/>\n      melanoma and disease progression following ipilimumab and, if BRAF V600<br \/>\n      mutation positive, a BRAF inhibitor. This indication is approved under<br \/>\n      accelerated approval based on tumor response rate and durability of<br \/>\n      response. An improvement in survival or disease-related symptoms has not<br \/>\n      yet been established. Continued approval for this indication may be<br \/>\n      contingent upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials.\n    <\/p>\n<p>\n      KEYTRUDA is the first anti-PD-1 (programmed death receptor-1) therapy<br \/>\n      approved in the United States and received FDA\u2019s Breakthrough Therapy<br \/>\n      designation for advanced melanoma, which was granted based on the<br \/>\n      significance of early study findings and the unmet medical need. For the<br \/>\n      recommended 2 mg\/kg dose based on data in 89 patients, the overall<br \/>\n      response rate was 24 percent (95% CI: 15, 34), with one complete<br \/>\n      response and 20 partial responses (21\/89). At the time of analysis, 86<br \/>\n      percent (18\/21) of patients with objective responses had ongoing<br \/>\n      responses with durations ranging from 1.4+ to 8.5+ months, including<br \/>\n      eight patients with ongoing responses of 6 months or longer. Fourteen<br \/>\n      percent (3\/21) had progression of disease 2.8, 2.9, and 8.2 months after<br \/>\n      initial response.\n    <\/p>\n<p>\n      KEYTRUDA is a humanized monoclonal antibody that works by increasing the<br \/>\n      ability of the body\u2019s immune system to fight advanced melanoma. KEYTRUDA<br \/>\n      blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2,<br \/>\n      and may affect both tumor cells and healthy cells. Immune-mediated<br \/>\n      adverse reactions occurred with KEYTRUDA including pneumonitis, colitis,<br \/>\n      hepatitis, hypophysitis, nephritis, hyperthyroidism, and hypothyroidism.<br \/>\n      Based on the severity of the adverse reaction, KEYTRUDA should be<br \/>\n      withheld or discontinued and corticosteroids administered. Based on its<br \/>\n      mechanism of action, KEYTRUDA may cause fetal harm when administered to<br \/>\n      a pregnant woman. Female patients of reproductive potential should be<br \/>\n      advised of the potential hazard to a fetus. For more information<br \/>\n      regarding immune-mediated adverse reactions and use in pregnancy, see<br \/>\n      \u201cSelected Important Safety Information\u201d below.\n    <\/p>\n<p>\n      \u201cKEYTRUDA embodies Merck\u2019s unwavering commitment to pursue breakthrough<br \/>\n      science to help people who are facing the most challenging diseases,\u201d<br \/>\n      said Kenneth C. Frazier, chairman and chief executive officer, Merck.<br \/>\n      \u201cWe are grateful to the people with advanced melanoma who participated<br \/>\n      in our trials, and the scientific and medical community for the shared<br \/>\n      effort that has led to the accelerated approval of KEYTRUDA.\u201d\n    <\/p>\n<p>\n      \u201cThe accelerated FDA approval of KEYTRUDA is a meaningful development<br \/>\n      for patients with advanced melanoma,\u201d said Dr. Omid Hamid, Director of<br \/>\n      the Melanoma Center at The Angeles Clinic and Research Institute, and a<br \/>\n      principal investigator for the pembrolizumab melanoma clinical program.<br \/>\n      \u201cOur new ability to target the PD-1 pathway with KEYTRUDA is a very<br \/>\n      exciting step in the immunotherapy field.\u201d\n    <\/p>\n<p>\n      Merck is conducting ongoing Phase 2 and 3 clinical studies in advanced<br \/>\n      melanoma, which are designed to provide further confirmatory evidence<br \/>\n      for KEYTRUDA in this indication. Merck plans to make KEYTRUDA available<br \/>\n      within one week from today\u2019s FDA approval.\n    <\/p>\n<p>\n      <b>Study Cohort Supporting the Accelerated FDA Approval of Single-Agent<br \/>\n      KEYTRUDA<\/b>\n    <\/p>\n<p>\n      The approval of KEYTRUDA was based on data from a multi-center,<br \/>\n      open-label, randomized, dose-comparative study cohort of the ongoing<br \/>\n      KEYNOTE-001 Phase 1b trial in patients with unresectable or metastatic<br \/>\n      melanoma and progression of disease. Key eligibility criteria included<br \/>\n      prior treatment with ipilimumab (two or more doses at 3 mg\/kg or higher)<br \/>\n      and a BRAF or MEK inhibitor, if BRAF V600 mutation positive; and disease<br \/>\n      progression within 24 weeks following the last dose of ipilimumab.<br \/>\n      Patients were randomized to receive 2 mg\/kg (n=89) or 10 mg\/kg (n=84) of<br \/>\n      KEYTRUDA every 3 weeks until unacceptable toxicity or disease<br \/>\n      progression. The major efficacy outcome measures were confirmed overall<br \/>\n      response rate as assessed by blinded independent central review using<br \/>\n      Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and duration<br \/>\n      of response. Tumor response was assessed every 12 weeks.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b>\n    <\/p>\n<p>\n      Pneumonitis occurred in 12 (2.9%) of 411 patients, including Grade 2 or<br \/>\n      3 cases in 8 (1.9%) and 1 (0.2%) patients respectively, receiving<br \/>\n      KEYTRUDA. Monitor patients for signs and symptoms of pneumonitis.<br \/>\n      Evaluate suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4<br \/>\n      pneumonitis.\n    <\/p>\n<p>\n      Colitis (including microscopic colitis) occurred in 4 (1%) of 411<br \/>\n      patients, including Grade 2 or 3 cases in 1 (0.2%) and 2 (0.5%) patients<br \/>\n      respectively, receiving KEYTRUDA. Monitor patients for signs and<br \/>\n      symptoms of colitis. Administer corticosteroids for Grade 2 or greater<br \/>\n      colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue<br \/>\n      KEYTRUDA for Grade 4 colitis.\n    <\/p>\n<p>\n      Hepatitis (including autoimmune hepatitis) occurred in 2 (0.5%) of 411<br \/>\n      patients, including a Grade 4 case in 1 (0.2%) patient, receiving<br \/>\n      KEYTRUDA. Monitor patients for changes in liver function. Administer<br \/>\n      corticosteroids for Grade 2 or greater hepatitis and, based on severity<br \/>\n      of liver enzyme elevations, withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Hypophysitis occurred in 2 (0.5%) of 411 patients, including a Grade 2<br \/>\n      case in 1 and a Grade 4 case in 1 (0.2% each) patient, receiving<br \/>\n      KEYTRUDA. Monitor for signs and symptoms of hypophysitis. Administer<br \/>\n      corticosteroids for Grade 2 or greater hypophysitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; withhold or discontinue for Grade 3; and permanently<br \/>\n      discontinue KEYTRUDA for Grade 4 hypophysitis.\n    <\/p>\n<p>\n      Nephritis occurred in 3 (0.7%) patients receiving KEYTRUDA, consisting<br \/>\n      of one case of Grade 2 autoimmune nephritis (0.2%) and two cases of<br \/>\n      interstitial nephritis with renal failure (0.5%), one Grade 3 and one<br \/>\n      Grade 4. Monitor patients for changes in renal function. Administer<br \/>\n      corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA for<br \/>\n      Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Hyperthyroidism occurred in 5 (1.2%) of 411 patients, including Grade 2<br \/>\n      or 3 cases in 2 (0.5%) and 1 (0.2%) patients respectively, receiving<br \/>\n      KEYTRUDA. Hypothyroidism occurred in 34 (8.3%) of 411 patients,<br \/>\n      including a Grade 3 case in 1 (0.2%) patient, receiving KEYTRUDA.<br \/>\n      Thyroid disorders can occur at any time during treatment. Monitor<br \/>\n      patients for changes in thyroid function (at the start of treatment,<br \/>\n      periodically during treatment, and as indicated based on clinical<br \/>\n      evaluation) and for clinical signs and symptoms of thyroid disorders.<br \/>\n      Administer corticosteroids for Grade 3 or greater hyperthyroidism.<br \/>\n      Withhold KEYTRUDA for Grade 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 hyperthyroidism. Isolated hypothyroidism may be managed with<br \/>\n      replacement therapy without treatment interruption and without<br \/>\n      corticosteroids.\n    <\/p>\n<p>\n      The following clinically significant, immune-mediated adverse reactions<br \/>\n      occurred in less than 1% of patients treated with KEYTRUDA: exfoliative<br \/>\n      dermatitis, uveitis, arthritis, myositis, pancreatitis, hemolytic<br \/>\n      anemia, partial seizures arising in a patient with inflammatory foci in<br \/>\n      brain parenchyma, adrenal insufficiency, myasthenic syndrome, optic<br \/>\n      neuritis, and rhabdomyolysis.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA may cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA was discontinued for adverse reactions in 6% of 89 patients who<br \/>\n      received the recommended dose of 2 mg\/kg and 9% of 411 patients across<br \/>\n      all doses studied. Serious adverse reactions occurred in 36% of patients<br \/>\n      receiving KEYTRUDA. The most frequent serious adverse drug reactions<br \/>\n      reported in 2% or more of patients were renal failure, dyspnea,<br \/>\n      pneumonia, and cellulitis.\n    <\/p>\n<p>\n      The most common adverse reactions (reported in \u226520% of patients) were<br \/>\n      fatigue (47%), cough (30%), nausea (30%), pruritus (30%), rash (29%),<br \/>\n      decreased appetite (26%), constipation (21%), arthralgia (20%), and<br \/>\n      diarrhea (20%).\n    <\/p>\n<p>\n      The recommended dose of KEYTRUDA is 2 mg\/kg administered as an<br \/>\n      intravenous infusion over 30 minutes every three weeks until disease<br \/>\n      progression or unacceptable toxicity. No formal pharmacokinetic drug<br \/>\n      interaction studies have been conducted with KEYTRUDA.\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA. Safety and effectiveness of KEYTRUDA<br \/>\n      have not been established in pediatric patients.\n    <\/p>\n<p>\n      <b>Commitment to Access for KEYTRUDA<\/b>\n    <\/p>\n<p>\n      Merck is committed to making KEYTRUDA accessible to patients.<br \/>\n      Reimbursement support for eligible patients receiving KEYTRUDA,<br \/>\n      including help with out-of-pocket costs and co-pay assistance, is<br \/>\n      available through <span class=\"bwuline\">The <\/span><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.merckaccessprogram-keytruda.com%2F&#038;esheet=50936549&#038;newsitemid=20140904006251&#038;lan=en-US&#038;anchor=Merck+Access+Program&#038;index=1&#038;md5=8f271e6e8e5d9ffffee833441b5005d3\" rel=\"nofollow\">Merck<br \/>\n      Access Program<\/a>. For eligible patients who are uninsured, financial<br \/>\n      assistance is available through Merck\u2019s patient assistance program. More<br \/>\n      information is available by calling 1-855-257-3932 or visiting <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.merckaccessprogram-keytruda.com&#038;esheet=50936549&#038;newsitemid=20140904006251&#038;lan=en-US&#038;anchor=www.merckaccessprogram-keytruda.com&#038;index=2&#038;md5=233782891b1380d8a8ab828b423ee519\" rel=\"nofollow\">www.merckaccessprogram-keytruda.com<\/a>.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b>\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) is a humanized monoclonal antibody that blocks<br \/>\n      the interaction between PD-1 and its ligands, PD-L1 and PD-L2. By<br \/>\n      binding to the PD-1 receptor and blocking the interaction with the<br \/>\n      receptor ligands, KEYTRUDA releases the PD-1 pathway-mediated inhibition<br \/>\n      of the immune response, including the anti-tumor immune response.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into biomedical<br \/>\n      innovations to help people with cancer worldwide. For Merck Oncology,<br \/>\n      helping people fight cancer is our passion, supporting accessibility to<br \/>\n      our cancer medicines is our commitment, and pursuing research in<br \/>\n      immuno-oncology is our focus to potentially bring new hope to people<br \/>\n      with cancer. For more information about our oncology clinical trials,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&#038;esheet=50936549&#038;newsitemid=20140904006251&#038;lan=en-US&#038;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&#038;index=3&#038;md5=681730520d3e9d272a630c7c1fa40603\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&#038;esheet=50936549&#038;newsitemid=20140904006251&#038;lan=en-US&#038;anchor=vip2-msd.com\/merckcom-migrated&#038;index=4&#038;md5=1bf0352564a6ba936d3d19fbc1f1f817\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=https%3A%2F%2Ftwitter.com%2Fmerck&#038;esheet=50936549&#038;newsitemid=20140904006251&#038;lan=en-US&#038;anchor=Twitter&#038;index=5&#038;md5=cac75e8ae6be62712246be420a4c2bba\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.facebook.com%2Fmerckbewell&#038;esheet=50936549&#038;newsitemid=20140904006251&#038;lan=en-US&#038;anchor=Facebook&#038;index=6&#038;md5=20104218d253df3f1e74f479b6f838e2\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.youtube.com%2Fmerck&#038;esheet=50936549&#038;newsitemid=20140904006251&#038;lan=en-US&#038;anchor=YouTube&#038;index=7&#038;md5=cddded2b7411c1732699840b371f8cbf\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include, but are not limited to, general<br \/>\n      industry conditions and competition; general economic factors, including<br \/>\n      interest rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and healthcare legislation in the<br \/>\n      United States and internationally; global trends toward healthcare cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2013 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sec.gov&#038;esheet=50936549&#038;newsitemid=20140904006251&#038;lan=en-US&#038;anchor=www.sec.gov&#038;index=8&#038;md5=53bcb46a4d8e9fca07b6317374932f8b\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&#038;esheet=50936549&#038;newsitemid=20140904006251&#038;lan=en-US&#038;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&#038;index=9&#038;md5=e77927e6789a0d40afc2cabfd941c330\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><\/a><b><br \/>\n      and the Medication Guide for KEYTRUDA at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&#038;esheet=50936549&#038;newsitemid=20140904006251&#038;lan=en-US&#038;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&#038;index=10&#038;md5=5fb393beb066e6aec26a181d733f2445\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><\/a><b>.<\/b>\n    <\/p>\n<p>\n      <b>RELATED MATERIALS<\/b>\n    <\/p>\n<p>\n      <b>To download multimedia assets, <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.multivu.com%2Fplayers%2FEnglish%2F7248751-merck-keytruda-fda-approval-melanoma%2F&#038;esheet=50936549&#038;newsitemid=20140904006251&#038;lan=en-US&#038;anchor=click+here&#038;index=11&#038;md5=373437879bc794dd98187d13fb0d85f9\" rel=\"nofollow\"><b>click<br \/>\n      here<\/b><\/a><b> to view the Multimedia News Release on MultiVu.<\/b>\n    <\/p>\n<p>\n      <b>KEYTRUDA<\/b><sup><b>\u00ae <\/b><\/sup><b>is a registered trademark of Merck<br \/>\n      Sharp &#038; Dohme Corp., a subsidiary of Merck &#038; Co., Inc.<\/b>\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&#038;sty=20140904006251r1&#038;sid=hq1sc1&#038;distro=nx&#038;lang=en\" \/><span class=\"bwct31415\"\/><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Ian McConnell, 908-423-3046<br \/>or<br \/>Claire        Mulhearn, 908-423-7425<br \/>or<br \/>Investor:<br \/>Joseph Romanelli,        908-423-5185<br \/>or<br \/>Justin Holko, 908-423-5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA\u00ae (pembrolizumab) at a dose of 2 mg\/kg every three weeks for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. This indication is approved under accelerated approval based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. KEYTRUDA is the first anti-PD-1 (programmed death receptor-1) therapy approved in the United States and received FDA\u2019s Breakthrough Therapy designation for advanced melanoma, which was granted based on the significance of early study findings and the unmet medical need. For the<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,55,289],"class_list":["post-744934","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Receives Accelerated Approval of KEYTRUDA\u00ae (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-accelerated-approval-of-keytruda-pembrolizumab-the-first-fda-approved-anti-pd-1-therapy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Receives Accelerated Approval of KEYTRUDA\u00ae (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA\u00ae (pembrolizumab) at a dose of 2 mg\/kg every three weeks for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. This indication is approved under accelerated approval based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. KEYTRUDA is the first anti-PD-1 (programmed death receptor-1) therapy approved in the United States and received FDA\u2019s Breakthrough Therapy designation for advanced melanoma, which was granted based on the significance of early study findings and the unmet medical need. For the\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-accelerated-approval-of-keytruda-pembrolizumab-the-first-fda-approved-anti-pd-1-therapy\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:51+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140904006251r1&sid=hq1sc1&distro=nx&lang=en\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-accelerated-approval-of-keytruda-pembrolizumab-the-first-fda-approved-anti-pd-1-therapy\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-accelerated-approval-of-keytruda-pembrolizumab-the-first-fda-approved-anti-pd-1-therapy\\\/\",\"name\":\"Merck Receives Accelerated Approval of KEYTRUDA\u00ae (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-accelerated-approval-of-keytruda-pembrolizumab-the-first-fda-approved-anti-pd-1-therapy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-accelerated-approval-of-keytruda-pembrolizumab-the-first-fda-approved-anti-pd-1-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20140904006251r1&sid=hq1sc1&distro=nx&lang=en\",\"datePublished\":\"2014-09-04T14:15:00+00:00\",\"dateModified\":\"2023-03-22T04:04:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-accelerated-approval-of-keytruda-pembrolizumab-the-first-fda-approved-anti-pd-1-therapy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-accelerated-approval-of-keytruda-pembrolizumab-the-first-fda-approved-anti-pd-1-therapy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-accelerated-approval-of-keytruda-pembrolizumab-the-first-fda-approved-anti-pd-1-therapy\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20140904006251r1&sid=hq1sc1&distro=nx&lang=en\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20140904006251r1&sid=hq1sc1&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-accelerated-approval-of-keytruda-pembrolizumab-the-first-fda-approved-anti-pd-1-therapy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Receives Accelerated Approval of KEYTRUDA\u00ae (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Receives Accelerated Approval of KEYTRUDA\u00ae (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-accelerated-approval-of-keytruda-pembrolizumab-the-first-fda-approved-anti-pd-1-therapy\/","og_locale":"en_US","og_type":"article","og_title":"Merck Receives Accelerated Approval of KEYTRUDA\u00ae (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA\u00ae (pembrolizumab) at a dose of 2 mg\/kg every three weeks for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. This indication is approved under accelerated approval based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. KEYTRUDA is the first anti-PD-1 (programmed death receptor-1) therapy approved in the United States and received FDA\u2019s Breakthrough Therapy designation for advanced melanoma, which was granted based on the significance of early study findings and the unmet medical need. For the","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-accelerated-approval-of-keytruda-pembrolizumab-the-first-fda-approved-anti-pd-1-therapy\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:51+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140904006251r1&sid=hq1sc1&distro=nx&lang=en","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-accelerated-approval-of-keytruda-pembrolizumab-the-first-fda-approved-anti-pd-1-therapy\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-accelerated-approval-of-keytruda-pembrolizumab-the-first-fda-approved-anti-pd-1-therapy\/","name":"Merck Receives Accelerated Approval of KEYTRUDA\u00ae (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-accelerated-approval-of-keytruda-pembrolizumab-the-first-fda-approved-anti-pd-1-therapy\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-accelerated-approval-of-keytruda-pembrolizumab-the-first-fda-approved-anti-pd-1-therapy\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140904006251r1&sid=hq1sc1&distro=nx&lang=en","datePublished":"2014-09-04T14:15:00+00:00","dateModified":"2023-03-22T04:04:51+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-accelerated-approval-of-keytruda-pembrolizumab-the-first-fda-approved-anti-pd-1-therapy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-accelerated-approval-of-keytruda-pembrolizumab-the-first-fda-approved-anti-pd-1-therapy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-accelerated-approval-of-keytruda-pembrolizumab-the-first-fda-approved-anti-pd-1-therapy\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140904006251r1&sid=hq1sc1&distro=nx&lang=en","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140904006251r1&sid=hq1sc1&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-accelerated-approval-of-keytruda-pembrolizumab-the-first-fda-approved-anti-pd-1-therapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Receives Accelerated Approval of KEYTRUDA\u00ae (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"e576accb-5f6d-475c-96b6-6be92ddf28aa","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744934","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744934\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=744934"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=744934"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}